【SUNZEN 0148 交流专区】宏诚生科

icy97

Type	Announcement
Subject	OTHERS
Description	- REVALUATION OF NON-CURRENT ASSETS
In accordance with Rule 9.19(46) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors (“Board”) of Sunzen Biotech Berhad (“Sunzen” or “Company”) wishes to inform that the Board of Sunzen had on 28 August 2024 approved the valuation report for the properties held by its subsidiaries and the incorporation of the revaluation surplus of RM9,868,610 into the Group’s unaudited financial results on consolidated results for the financial quarter ended 30 June 2024. Please refer to the attachment for the details of the announcement. This announcement is dated 29 August 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3479222

Attachments Revaluation of Non-Current Assets.pdf

icy97

SUNZEN BIOTECH BERHAD

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-23092024-00001
Subject	Article Entitled: "Sunzen Biotech aims to sell assets"
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "THE COMPANY)Article Entitled: "Sunzen Biotech aims to sell assets"
Query Letter Contents	We refer to the above media article appearing in NewStraitsTimes dated 23 September 2024, a copy of which is enclosed for your reference. In particular, we would like to draw your attention to the underlined sentence which is reproduced as follows :- "Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16million and RM18million." In accordance with Bursa Securities' Corporate Disclosure Policy, kindly furnish Bursa Securities with an announcement for public release confirming or denying the above reported article in particular the underlined sentences after due and diligent enquiry with all the directors, major shareholders and all such other person reasonably familiar with the matters about which the disclosure is to made in this respect. In the event you deny the above reported sentences or any other part of the article, you are required to set forth facts sufficient to support the same.
Clarification on the Article Published in The New Straits Times on 23 September 2024With reference to the article titled "Sunzen Biotech Aims to Sell Assets" published in The New Straits Times on 23 September 2024 (the "Article"), specifically regarding the statement:“Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16 million and RM18 million.”The Board of Directors of Sunzen Biotech Berhad ("the Board") has conducted a thorough inquiry involving all directors, major shareholders, and management regarding recent media inquiries dated 20 September 2024. The Board wish to clarify that while the management referenced the matter during these press inquiries, this was in the context of an initial study and planning phase related to the cessation of our animal health division, which the Company has previously announced on 8 April 2024.It is important to note that the discussions are still exploratory and have not yet been presented to the Board for further consideration. Additionally, the valuation amount mentioned in the article is based on a recent valuation conducted by the Sunzen Group’s properties, which was announced on 29 August 2024.Once the feasibility study is finalised and the Board’s approval is obtained, the Company will make the necessary announcements to Bursa Malaysia Securities Berhad.This announcement is dated 24 September 2024.

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("THE COMPANY" OR "SUNZEN") -        ACQUISITION OF SHARES IN EYE NATION MEDICAL SDN. BHD.
Further to the Company’s announcement on 6 May 2024, the Board of Directors of Sunzen (“Board”) wishes to announce that the Company, had on 1 October 2024 entered into a Share Sale Agreement (“SSA”) with Mr. Lee Peng Hwa (“Lee”) and Madam Lay Lee Chin (“Lay”) (collectively referred to as “the Vendors”), for the acquisition of seventy thousand (70,000) ordinary shares (“Sale Shares”), representing seventy percent (70%) of the equity interest of Eye Nation Medical Sdn. Bhd. [Registration No. 200301031140 (633561-V)] (“ENMSB”) for a total cash consideration of Ringgit Malaysia Six Million Three Hundred and Seventy Thousand (RM6,370,000.00) only (“Purchase Price”) (“the Acquisition”) in accordance with the terms and conditions of the SSA. Please refer to the attachment for details of the announcement. This announcement is dated 1 October 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3488216

Attachments Sunzen_Ann_Acq of Shares_Eye Nation_FINAL.pdf